Immunic Analyst Ratings
Immunic Stock's Popularity Rises With Consistent Buy Ratings From Analysts
Brookline Capital Maintains Immunic(IMUX.US) With Buy Rating, Raises Target Price to $13
Analysts Are Bullish on Top Healthcare Stocks: Bluebird Bio (BLUE), Immunic (IMUX)
B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6
B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6
Buy Rating Affirmed for Immunic, Inc. on Promising MS Drug Developments and Favorable Market Position
Immunic Price Target Announced at $17.00/Share by EF Hutton
Immunic Initiated at Buy by EF Hutton
Immunic Analyst Ratings
Leerink Partners Initiates Immunic(IMUX.US) With Buy Rating, Announces Target Price $5
Piper Sandler Sticks to Their Buy Rating for Immunic (IMUX)
Immunic Initiated at Buy by B. Riley Securities
Immunic Price Target Announced at $6.00/Share by B. Riley Securities
Immunic Analyst Ratings
B.Riley Financial Initiates Immunic(IMUX.US) With Buy Rating, Announces Target Price $6
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Aldeyra Therapeutics (ALDX) and Immunic (IMUX)
Immunic Analyst Ratings
Hold Rating on Immunic Amidst Ongoing Vido Clinical Trials and Financial Outlook
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)